Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466656 | 0.83 | MAPK14 (0.65) | MAPK14MAPK11LCKMAP2K1 | |
| SCHEMBL5458558 | 0.83 | MAPK14 (0.65) | MAPK14MAPK11LCKMAP2K1 | |
| SCHEMBL5466893 | 0.79 | MAPK14 (0.62) | MAPK14MAPK11MAP2K1 | |
| SCHEMBL5471452 | 0.78 | MAPK14 (0.69) | MAPK14MAPK11LCKMAP2K1 | |
| SCHEMBL5458542 | 0.78 | MAPK14 (0.68) | MAPK14MAPK11LCKMAP2K1 | |
| SCHEMBL5458638 | 0.78 | MAPK14 (0.65) | MAPK14MAPK11MAP2K1 | |
| SCHEMBL4855098 | 0.77 | MAPK14 (0.77) | MAPK14MAPK11LCKMAP2K1 | |
| SCHEMBL5462093 | 0.76 | MAPK14 (0.77) | MAPK14MAPK11MAP2K1 | |
| SCHEMBL5467937 | 0.76 | MAPK14 (0.61) | MAPK14MAPK11LCKMAP2K1 | |
| SCHEMBL4858353 | 0.76 | MAPK14 (1.00) | MAPK14MAPK11LCKMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112046-A1 | 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-17 | — | — | US | claimed |
| US-7166623-B2 | 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | claimed |
| US-20070112046-A1 | 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-05-17 | — | — | US | disclosed |
| US-7166623-B2 | 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20050090491-A1 | 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| EP-1435950-A1 | 2'-METHYL-5'-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032987-A1 | 2'-METHYL-5'-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112046-A1 | 2'-Methyl-5'-(1,3,4-Oxadiazol-2-yl)-1,1'-Biphenyl-4-Carboxamide Derivatives and Their Use As P38 Kinase Inhibitors | MAPK1, MAPK3, MAPKAPK2 | MAPK14 7/4885MAPK11 36/4885LCK 48/4885 |
| US-20050090491-A1 | 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GRK4, MAPK4, MAPK1 | MAPK14 19/4885MAPK11 64/4885LCK 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.